The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA

Journal of Immunological Methods

Volumn 203, Issue 1, 1997, Pages 55-65

  Pedersen, Anders N ^a   Høyer Hansen, Gunilla ^a   Brünner, Nils ^a   Clark, Gary M ^b   Larsen, Birthe ^a   Poulsen, Hans S ^c   Danø, Keld ^a   Stephens, Ross W ^a  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Rigshospitalet   (Denmark)

Author keywords

Breast cancer; Complex; Enzyme linked immunosorbent assay; Invasion; Plasminogen activator inhibitor type 1; Urokinase plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR EXTRACT;

ARTICLE; BIOTINYLATION; BREAST CANCER; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; BUFFERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; MULTIENZYME COMPLEXES; PLASMINOGEN ACTIVATORS; SENSITIVITY AND SPECIFICITY; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030934442     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(97)00008-2     Document Type: Article

References (58)

1. Andreasen, P.A., Nielsen, L.S., Kristensen, P., Grøndahl-Hansen, J., Skriver, L. and Danø, K. (1986) Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator but not its proenzyme. J. Biol. Chem. 261, 7644.
2. Andreasen, P.A., Georg, B., Lund, L.R., Riccio, A. and Stacey, S.N. (1990) Plasminogen activator inhibitors: hormonally regulated serpins. Mol. Cell. Endocrinol. 68, 1.
3. Andreasen, P.A., Sottrup-Jensen, L., Kjøller, L., Nykjær, A., Moestrup, S.K., Petersen, C.M. and Gliemann, J. (1994) Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett. 338, 239.
4. Barlough, J.E., Jacobson, R.H., Downing, D.R., Marcella, K.L., Lynch, T.J. and Scott, F.W. (1983) Evaluation of a computer-assisted, kinetics-based enzyme-linked immuno sorbent assay for detection of coronavirus antibodies in cats. J. Clin. Microbiol. 17, 202.
5. Benraad, Th.J., Geurts-Moespot, J., Grøndahl-Hansen, J., Schmitt, M., Heuvel, J.J.T.M., de Witte, J.H., Foekens, J.A., Leake, R.E., Brünner, N. and Sweep, C.G.J. (1996) Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur. J. Cancer 32A, 1371.
6. Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248.
7. Camiolo, S.M., Suita, M.R. and Madeja, J.M. (1982) Improved medium for extraction of plasminogen activator from tissue. Preparative Biochem. 12, 297.
8. 2-macroglobulin receptor in human breast carcinomas. Int. J. Cancer 66, 441.
9. Cubellis, M.V., Wun, T.-C. and Blasi, F. (1990) Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 9, 1079.
10. Danø, K., Andreasen, P.A., Grøndahl-Hansen, J., Kristensen, P., Nielsen, L.S. and Skriver, L. (1985) Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44, 139.
11. Danø, K., Behrendt, N., Brünner, N., Ellis, V., Ploug, M. and Pyke, C. (1994) The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8 (Suppl. 1), 189.
12. Declerck, P.J., De Mol, M., Allessi, M.C., Baudner, S., Paques, E.P., Preissner, K.T., Muller Berghaus, G. and Collen, D. (1988) Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J. Biol. Chem. 263, 15454.
13. Duffy, M.J., O'Grady, P., Devaney, D., O'Siorain, L., Fennelly, J.J. and Lijnen, H. (1988) Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer 62, 531.
14. Duffy, M.J., Reilly, D., O'Sullivan, C., O'Higgins, N., Fennelly, J.J. and Andreasen, P. (1990) Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 50, 6827.
15. Ellis, V., Scully, M.F. and Kakkar, V.V. (1989) Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J. Biol. Chem. 264, 2185.
16. Ellis, V., Pyke, C., Eriksen, J., Solberg, H. and Danø, K. (1992) The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann. New York Acad. Sci. 667, 13.
17. EORTC (European Organization for Research and Treatment of Cancer) Breast Co-operative Group (1980) Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur. J. Cancer 16, 1513.
18. Foekens, J.A., Schmitt, M., van Putten, W.L.J., Peters, H.A., Bontenbal, M., Jänicke, F. and Klijn, J.G.M. (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 52, 6101.
19. Foekens, J.A., Schmitt, M., van Putten, W.L.J., Peters, Kramer, M.D., Jänicke, F. and Klijn, J.G.M. (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J. Clin. Oncol. 12, 1648.
20. Ganesh, S., Sier, C.F.M., Griffioen, G., Vloedgraven, H.J.M., de Boer, A., Welvaart, K., van de Velde, C.J.H., van Krieken, J.H.J.M., Verheijen, J.H., Lamers, C.B.H.W. and Verspaget, H.W. (1994) Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res. 54, 4065.
21. Grøndahl-Hansen, J., Agerlin, N., Munkholm-Larsen, P., Bach, F., Nielsen, L.S., Dombernowsky, P. and Danø, K. (1988) Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J. Lab. Clin. Med. 111, 42.
22. Grøndahl-Hansen, J., Christensen, I.J., Rosenquist, C., Brünner, N., Mouridsen, H.T., Danø, K. and Blichert-Toft, M. (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53, 2513.
23. Guesdon, J.-L., Ternynck, T. and Avrameas, S. (1979) The use of avidin-biotin interaction in immunoenzymatic techniques. J. Histochem. Cytochem. 27, 1131.
24. Hancock, K. and Tsang, V.C.W. (1986) Development and optimization of the FAST-ELISA for detecting antibodies to Shistosoma mansoni. J. Immunol. Methods 92, 167.
25. Jänicke, F., Schmitt, M. and Graeff, H. (1991) Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Throm. Hemost. 17, 303.
26. Jänicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Höfler, H. and Graeff, H. (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in nodenegative breast cancer. Breast Cancer Res. Treat. 24, 195.
27. Jänicke, F., Pache, L., Schmitt, M., Ulm, K., Thomssen, C., Prechtl, A. and Graeff, H. (1994) Both the cytosols and the detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res. 54, 2527.
28. Jensen, P.H., Christensen, E.I., Ebbesen, P., Gliemann, J. and Andreasen, P.A. (1990) Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells. Cell. Reg. 1, 1043.
29. Keijer, J., Linders, M., van Zonnenveld, A.-J., Ehrlich, H.J., de Boer, J.P. and Pannekoek, H. (1991) The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiological relevance. Blood 78, 401.
30. Kielberg, V., Andreasen, P.A., Grøndahl-Hansen, J., Nielsen, L.S., Skriver, L. and Danø, K. (1985) Proenzyme to urokinase-type plasminogen activator in the mouse in vivo. FEBS Lett. 182, 441.
31. Kruithof, E.K.O., Tran-Thang, C. and Bachmann, F. (1986) The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb. Haemostasis 55, 65.
32. Kuhn, W., Pache, L., Schmalfeldt, B., Dettmar, M., Schmitt, M., Jänicke, F. and Graeff, H. (1995) Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gy. Oncol. 55, 401.
33. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951) Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265.
34. Lund, L.R., Georg, B., Nielsen, L.S., Mayer, M., Danø, K. and Andreasen, P.A. (1988) Plasminogen activator inhibitor type 1: cell-specific and differentiation-induced expression and regulation in human cell lines, as determined by enzyme-linked immunosorbent assay. Mol. Cell. Endocrinol. 60, 43.
35. Munch, M., Heegaard, C., Jensen, P.H. and Andreasen, P.A. (1991) Type-1 inhibitor of plasminogen activators. Distinction between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies. FEBS Lett. 295, 102.
36. Munch, M., Heegaard, C.W. and Andreasen, P.A. (1993) Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim. Biophys. Acta 1202, 29.
37. Nekarda, H., Schmitt, M., Ulm, K., Wenninger, A., Vogelsang, H., Becker, K., Roder, J.D., Fink, U. And Siewert, J.R. (1994) Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 54, 2900.
38. Nielsen, L.S., Hansen, J.G., Skriver, L., Wilson, E.L., Kaltoft, K., Zeuthen, J. and Danø, K. (1982) Purification of zymogen to plasminogen activator from human glio blastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 24, 6410.
39. Nielsen, L.S., Andreasen, P.A., Grøndahl-Hansen, J., Huang, J.-Y., Kristensen, P. and Danø, K. (1986a) Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells-inhibitor neutralization and one-step affinity purification. Thromb. Haemostasis 55, 206.
40. Nielsen, L.S., Grøndahl-Hansen, J., Andreasen, P.A., Skriver, L., Zeuthen, J. and Danø, K. (1986b) Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies. J. Immunoassay 7, 209.
41. r receptor protein for urokinase-type plasminogen activator: identification in human tumor cell lines and partial purification. J. Biol. Chem. 263, 2358.
42. Pappot, H., Gårdsvoll, H., Rømer, J., Pedersen, A.N., Grøndahl-Hansen, J., Pyke, C. and Brünner, N. (1995) Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol. Chem. Hoppe-Seyler 376, 259.
43. Pedersen, H., Grøndahl-Hansen, J., Francis, D., Østerlind, K., Hansen, H.H., Danø, K. and Brünner, N. (1994a) Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res. 54, 120.
44. Pedersen, H., Brünner, N., Francis, D., Østerlind, K., Rønne, E., Hansen, H.H., Danø, K. and Grøndahl-Hansen, J. (1994b) Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 54, 4671.
45. Philips, M., Juul, A.-G., Selmer, J., Lind, B. and Thorsen, S. (1992) A specific immunologic assay for functional plasminogen activator inhibitor 1 in plasma-standardized measurements of the inhibitor and related parameters in patients with venous thromboembolic disease. Thromb. Haemostasis 68, 486.
46. Pöllänen, J, Stephens, R.W. and Vaheri, A. (1991) Plasminogen activation at the surface of normal and malignant cells. Adv. Cancer Res. 57, 273.
47. Pyke, C., Kristensen, P., Ralfkiær, E., Eriksen, J. and Danø, K. (1991) The plasminogen activator system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in tumor stroma. Cancer Res. 51, 4067.
48. Reich, E. (1978) Activation of plasminogen: a general mechanism for producing localized extracellular proteolysis. In: R.D. Berlin, H. Herrmann, I.H. Lepow and J.M. Tanzer (Eds.), Molecular Basis of Biological Degradative Processes. Academic Press, New York, p. 155.
49. Reilly, D., Christensen, L., Duch, M., Nolan, N., Duffy, M.J. and Andreasen, P.A. (1992) Type-1 plasminogen activator inhibitor in human breast carcinomas. Int. J. Cancer 50, 208.
50. Rosenquist, C., Thorpe, S.M., Danø, K. and Grøndahl-Hansen, J. (1993) Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res. Treat. 28, 223.
51. Rønne, E., Høyer-Hansen, G., Brünner, N., Pedersen, H., Rank, F., Osborne, C.K., Clark, G.M., Danø, K. and Grøndahl-Hansen, J. (1995) Urokinase receptor in breast cancer extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res. Treat. 33, 199.
52. Shulman, M., Wilde, C.D. and Köhler, G. (1978) A better cell line for making hybridomas secreting specific antibodies. Nature 276, 269.
53. Skriver, L., Nielsen, L.S., Stephens, R. and Danø, K. (1982) Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus. Eur. J. Biochem. 124, 409.
54. Skriver, L., Larsson, L.-I., Kielberg, V., Nielsen, L.S., Andresen, P.B., Kristensen, P. and Danø, K. (1984) Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J. Cell. Biol. 99, 752.
55. Stephens, R.W., Pöllänen, J., Tapiovaara, H., Leung, K.C., Sim, P.S., Salonen, E.M., Rønne, E., Behrendt, N., Danø, K. and Vaheri, A. (1989) Activation of prourokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J. Cell. Biol. 108, 1987.
56. Tsang, V.C.W., Wilson, B.C. and Madison, S.E. (1980) Kinetic studies of a quantitative single-tube enzyme-linked immunosorbent assay. Clin. Chem. 26, 1255.
57. r 55,000 form of the plasminogen activator, urokinase. J. Cell. Biol. 100, 86.
58. Zucker, S., Lysik, R.M., DiMassimo, B.I., Zarrabi, H.M., Moll, U.M., Grimson, R., Tickle, S. and Docherty, A.J. (1995) Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer. Cancer 76, 700.